

CORDLIFE GROUP LIMITED
(Company Registration No.: 200102883E)
(Incorporated in the Republic of Singapore)

- (1) **RESPONSE TO MEDIA ARTICLE**
 - (2) **UPDATE ON TANKS UNDER INVESTIGATION**
-

The Board of Directors of Cordlife Group Limited (the "**Company**") refers to its announcements dated 30 November 2023 ("**30 November Announcement**"), 13 December 2023 and 15 December 2023, and the media article released by the Business Times on 15 January 2024 titled "*Cordlife probe finds temperature in one tank went as high as 20.4 deg C in 2021*" ("**Media Article**").

(1) **Response to Media Article**

As stated in the 30 November Announcement, the Company has been cooperating fully with the Ministry of Health ("**MOH**") on investigations on the tanks where irregular temperature readings were detected. As part of the ongoing process, the Company continues to cooperate fully with queries from all relevant regulatory authorities, including the MOH and the Singapore Exchange Regulation ("**SGX Regco**"), and has also been working closely with the MOH to investigate and address any identified issues. The Company notes the contents of the Media Article but given that investigations are currently ongoing, the Company is unable to comment further. Nonetheless, the Company notes that the Media Article had stated that certain affected tanks had out-of-range temperature fluctuations based on tank controller temperature data between November 2020 and July 2022. However, the Company wishes to clarify that the information on the temperature excursions is mainly obtained from the Laboratory Environment Monitoring Alarm System, and not tank controller temperature data. The tank controller temperature data is mainly used to support the findings that tank temperatures are within the acceptable range for certain affected tanks.

(2) **Update on Tanks under investigation**

Since the end of December 2023, the Company has started sending donated cord blood samples from the affected tanks under investigation to a third-party laboratory in Singapore licensed by MOH for testing in batches. To date, donated cord blood samples from five tanks have been sent and the Company aims to complete the sending of samples from all the affected tanks by 18 January 2024. The nature of the tests is such that each batch may take between 3 and 6 weeks to be completed, depending on whether there is a need to conduct repeat testing of samples from the same tank. Samples from the remaining unaffected tanks will also undergo testing in due course.

The Company has updated affected clients on the above, and will be notifying them as soon as their relevant test results are available. In the interim, the Company will continue to work closely with MOH to investigate and address any identified issues, as well as strengthen its processes and procedures.

The Company will update its shareholders and the investing public, if there are any material developments in relation to the above, in accordance with the requirements of the SGX-ST listing rules.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Tan Poh Lan
Executive Director and Group CEO

17 January 2024